Ardelyx Inc (ARDX) Stock falls 20% After Extension of the PDUFA Review Period

Ardelyx Inc (NASDAQ:ARDX) slumped after the company announced three-month extension of PDUFA review period for tenapanor.

Ardelyx Inc (ARDX) Stock falls 20% After Extension of the PDUFA Review Period

Ardelyx announced that the Prescription Drug User Fee Act (PDUFA) date for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis has been extended by three months.

Following constructive labeling discussions with the FDA that began in early April, the agency made a recent information request that required the company to submit additional analyses to help the agency better understand the clinical data in light of tenapanor’s novel mechanism of action as compared to approved therapies.

Related:  BIOLASE (BIOL) Has Turned Bullish After Last Week Rally

In response, the company submitted the requested analyses which constitute a major amendment to the New Drug Application, resulting in an extension of the PDUFA date by three months to July 29, 2021.

ARDX stock is down over 20% to $6.70 in after-hours session.

Jack Dawkins

Finance and Tech Contributor